- MW:157.1 Da
- Appearance:Off-white powder
- Purity:>99% by HPLC
Starting at $76.73
Favipiravir is an inhibitor of influenza viruses A, B, and C (IC50s: A = 0.03- 0.20 µg/mL H1N1; 0.01-0.30 H2N2; 0.08-0.48 H3N2; 0.14-0.15 H4N2; 0.24-1.60 H7N2; 0.20-0.82 H5N1; 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir1-3 . It displays no cytotoxicity in a variety of cell lines. Selectively inhibits viral RNA-dependent RNA polymerase4 . Displays activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses5 . In clinical trials for treatment of SARS-CoV-26,7.
Not for human therapeutic use or for medicinal purposes. For research applications only.
|Handling||Avoid contact with skin and eyes. Ventilation and proper handling are to be used to prevent the formation of dusts and mists. Normal measures for preventative fire protection. No smoking, eating or drinking around this material. Wash hands after use.|